

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Albania	Guyana	Pakistan
Algeria	Haiti	Panama
Argentina	Honduras	Peru
Armenia	Hong Kong	Qatar
Aruba	Israel	Republic of Korea
Australia	Jamaica	Saudi Arabia
Azerbaijan	Japan	Serbia
Bahrain	Jordan	Singapore
Bosnia and Herzegovina	Kazakhstan	South Africa
Botswana	Kenya	Switzerland
Brazil	Kuwait	Taiwan
Canada	Kyrgyzstan	Thailand
Chile	Lebanon	Trinidad and Tobago
China	Macau	Turkey
Colombia	Macedonia	Uganda
Costa Rica	Mexico	Ukraine
Curacao	Moldova	United Arab Emirates
Dominican Republic	Mongolia	United Kingdom
Ecuador	Morocco	United States of America
El Salvador	Namibia	Uruguay
European Union	New Zealand	Uzbekistan
Georgia	Nigeria	
Ghana	Oman	
Guatemala		

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 29 November 2022 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.